{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:45:29Z","timestamp":1788245129678,"version":"build-2803163510"},"reference-count":66,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002992","name":"Department for International Development, UK Government","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100002992","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bill and Melinda Gates Foundation","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}]},{"name":"Medical Research Council","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}]}],"content-domain":{"domain":["gatesopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Gates Open Res"],"abstract":"<ns4:p>\n                    The World Health Organization (WHO) has embarked on a consultation process to refine the 2030 goals for priority neglected tropical diseases (NTDs), onchocerciasis among them. Current goals include elimination of transmission (EOT) by 2020 in Latin America, Yemen and selected African countries. The new goals propose that, by 2030, EOT be verified in 10 countries; mass drug administration (MDA) with ivermectin be stopped in at least one focus in 34 countries; and that the proportion of the population no longer in need of MDA be equal or greater than 25%, 50%, 75% and 100% in at least 16, 14, 12, and 10 countries, respectively. The NTD Modelling Consortium onchocerciasis teams have used EPIONCHO and ONCHOSIM to provide modelling insights into these goals. EOT appears feasible in low-moderate endemic areas with long-term MDA at high coverage (\u226575%), but uncertain in areas of higher endemicity, poor coverage and adherence, and where MDA has not yet, or only recently, started. Countries will have different proportions of their endemic areas classified according to these categories, and this distribution of pre-intervention prevalence and MDA duration and programmatic success will determine the feasibility of achieving the proposed MDA cessation goals. Highly endemic areas would benefit from switching to biannual or quarterly MDA and implementing vector control where possible (determining optimal frequency and duration of anti-vectorial interventions requires more research). Areas without loiasis that have not yet initiated MDA should implement biannual (preferably with moxidectin) or quarterly MDA from the start. Areas with loiasis not previously treated would benefit from implementing test-and(not)-treat-based interventions, vector control, and anti-\n                    <ns4:italic>Wolbachia<\/ns4:italic>\n                    therapies, but their success will depend on the levels of screening and coverage achieved and sustained. The diagnostic performance of IgG4 Ov16 serology for assessing EOT is currently uncertain. Verification of EOT requires novel diagnostics at the individual- and population-levels.\n                  <\/ns4:p>","DOI":"10.12688\/gatesopenres.13067.1","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T13:58:31Z","timestamp":1569506311000},"page":"1545","update-policy":"https:\/\/doi.org\/10.12688\/gatesopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling"],"prefix":"10.12688","volume":"3","author":[{"name":"NTD Modelling Consortium Onchocerciasis Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"e0005424","DOI":"10.1371\/journal.pntd.0005424","article-title":"The global burden of disease study 2013: What does it mean for the NTDs?","volume":"11","author":"J Herricks","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-2","first-page":"681-94","article-title":"681 Progress report on the elimination of human onchocerciasis, 2016\u20132017.","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1932-41","DOI":"10.1086\/383326","article-title":"Incidence of blindness during the Onchocerciasis Control Programme in western Africa, 1971-2002.","volume":"189","author":"M Little","year":"2004","journal-title":"J Infect Dis."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1514-21","DOI":"10.1016\/S0140-6736(04)16151-5","article-title":"Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study.","volume":"363","author":"M Little","year":"2004","journal-title":"Lancet."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"e1578","DOI":"10.1371\/journal.pntd.0001578","article-title":"Density-dependent mortality of the human host in onchocerciasis: relationships between microfilarial load and excess mortality.","volume":"6","author":"M Walker","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1603-58","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.","volume":"388","year":"2016","journal-title":"Lancet."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1278-86","DOI":"10.1016\/S1473-3099(18)30425-0","article-title":"The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study.","volume":"18","author":"C Chesnais","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40249-018-0481-9","article-title":"Burden of onchocerciasis-associated epilepsy: first estimates and research priorities.","volume":"7","author":"N Vinkeles Melchers","year":"2018","journal-title":"Infect Dis Poverty."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"7-11","DOI":"10.1179\/136485908X337418","article-title":"The Mectizan Donation Program: 20 years of successful collaboration - a retrospective.","volume":"102 Suppl 1","author":"B Colatrella","year":"2008","journal-title":"Ann Trop Med Parasitol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"e2759","DOI":"10.1371\/journal.pntd.0002759","article-title":"African programme for onchocerciasis control 1995-2015: updated health impact estimates based on new disability weights.","volume":"8","author":"L Coffeng","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2883-2-2","article-title":"Final report of the Conference on the Eradicability of Onchocerciasis.","volume":"2","author":"Y Dadzie","year":"2003","journal-title":"Filaria J."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1475-2883-2-8","article-title":"Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination\/eradication in West-Africa.","volume":"2","author":"G Borsboom","year":"2003","journal-title":"Filaria J."},{"key":"ref-13","first-page":"384-91","article-title":"Can ivermectin mass treatments eliminate onchocerciasis in Africa?","volume":"80","author":"M Winnen","year":"2002","journal-title":"Bull World Health Organ."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1371\/journal.pntd.0000497","article-title":"Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.","volume":"3","author":"L Diawara","year":"2009","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"e1825","DOI":"10.1371\/journal.pntd.0001825","article-title":"Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal.","volume":"6","author":"M Traore","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-16","article-title":"Conceptual and Operational Framework of Onchocerciasis Elimination with Ivermectin Treatment","year":"2010"},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"18-22","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.","volume":"350","author":"J Gardon","year":"1997","journal-title":"Lancet."},{"key":"ref-18","first-page":"655-662","article-title":"[Epidemiologic status of onchocerciasis].","volume":"57","author":"A Prost","year":"1979","journal-title":"Bull World Health Organ."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"e0004328","DOI":"10.1371\/journal.pntd.0004328","article-title":"Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa.","volume":"10","author":"S O'Hanlon","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"347-51","DOI":"10.1016\/j.pt.2004.06.004","article-title":"Disease eradication, elimination and control: the need for accurate and consistent usage.","volume":"20","author":"D Molyneux","year":"2004","journal-title":"Trends Parasitol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"e115886","DOI":"10.1371\/journal.pone.0115886","article-title":"Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment.","volume":"9","author":"L Coffeng","year":"2014","journal-title":"PLoS One."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"310-22","DOI":"10.1016\/S1473-3099(08)70099-9","article-title":"Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.","volume":"8","author":"M Bas\u00e1\u00f1ez","year":"2008","journal-title":"Lancet Infect Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"204-10","DOI":"10.1093\/infdis\/172.1.204","article-title":"Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa.","volume":"172","author":"A Plaisier","year":"1995","journal-title":"J Infect Dis."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"2026-34","DOI":"10.1093\/cid\/cix616","article-title":"Macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness.","volume":"65","author":"M Walker","year":"2017","journal-title":"Clin Infect Dis."},{"key":"ref-25","article-title":"Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation","year":"2012"},{"key":"ref-26","article-title":"Eighteenth Session of the Joint Action Forum. Bujumbura, Burundi. Final Communique. 2012"},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s13071-015-1159-9","article-title":"Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.","volume":"8","author":"W Stolk","year":"2015","journal-title":"Parasit Vectors."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"247-341","DOI":"10.1016\/bs.apar.2016.08.003","article-title":"River blindness: Mathematical models for control and elimination.","volume":"94","author":"M Bas\u00e1\u00f1ez","year":"2016","journal-title":"Adv Parasitol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"4-15","DOI":"10.1016\/j.epidem.2017.02.005","article-title":"Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.","volume":"18","author":"M Walker","year":"2017","journal-title":"Epidemics."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"S267-S274","DOI":"10.1093\/cid\/cix1137","article-title":"How can onchocerciasis elimination in Africa be accelerated? Modeling the impact of increased ivermectin treatment frequency and complementary vector control.","volume":"66","author":"S Verver","year":"2018","journal-title":"Clin Infect Dis."},{"key":"ref-31","article-title":"Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: implications for elimination and data needs.","author":"J Hamley","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"669-79","DOI":"10.4269\/ajtmh.2002.67.669","article-title":"Transmission intensity and the patterns of Onchocerca volvulus infection in human communities.","volume":"67","author":"M Bas\u00e1\u00f1ez","year":"2002","journal-title":"Am J Trop Med Hyg."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"242-50","DOI":"10.1016\/s0035-9203(03)90132-5","article-title":"Density-dependent parasite establishment suggests infection-associated immunosuppression as an important mechanism for parasite density regulation in onchocerciasis.","volume":"97","author":"H Duerr","year":"2003","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"463-73","DOI":"10.1016\/j.ijpara.2003.11.008","article-title":"The relationships between the burden of adult parasites, host age and the microfilarial density in human onchocerciasis.","volume":"34","author":"H Duerr","year":"2004","journal-title":"Int J Parasitol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1069-74","DOI":"10.1016\/j.ijpara.2004.04.011","article-title":"Cattle protected from onchocerciasis by ivermectin are highly susceptible to infection after drug withdrawal.","volume":"34","author":"L Njongmeta","year":"2004","journal-title":"Int J Parasitol."},{"key":"ref-36","article-title":"Report of the Consultative Meetings on Strategic Options and Alternative Treatment Strategies for Accelerating Onchocerciasis Elimination in Africa","year":"2015"},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"i40-i48","DOI":"10.1093\/inthealth\/ihx054","article-title":"Alternative treatment strategies to accelerate the elimination of onchocerciasis.","volume":"10","author":"M Boussinesq","year":"2018","journal-title":"Int Health."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"923-32","DOI":"10.1093\/cid\/ciu467","article-title":"Reaching the London Declaration on Neglected Tropical Diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.","volume":"59","author":"H Turner","year":"2014","journal-title":"Clin Infect Dis."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"2044-52","DOI":"10.1056\/NEJMoa1705026","article-title":"A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas.","volume":"377","author":"J Kamgno","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"215-28","DOI":"10.1080\/00034983.1987.11812115","article-title":"Studies on the dynamics of transmission of onchocerciasis in a Sudan-savanna area of North Cameroon I. Prevailing Simulium vectors, their biting rates and age-composition at different distances from their breeding sites.","volume":"81","author":"A Renz","year":"1987","journal-title":"Ann Trop Med Parasitol."},{"key":"ref-41","first-page":"143-54","article-title":"The Onchocerca volvulus transmission potentials and associated patterns of onchocerciasis at four Cameroon Sudan-savanna villages.","volume":"26","author":"B Duke","year":"1975","journal-title":"Tropenmed Parasitol."},{"key":"ref-42","first-page":"346-54","article-title":"Transmission potentials of Onchocerca volvulus and the associated intensity of onchocerciasis in a Sudan-savanna area.","volume":"29","author":"B Thylefors","year":"1978","journal-title":"Tropenmed Parasitol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1367-72","DOI":"10.1016\/j.ijpara.2006.08.001","article-title":"High infection rates at low transmission potentials in West African onchocerciasis.","volume":"36","author":"H Duerr","year":"2006","journal-title":"Int J Parasitol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13071-016-1313-z","article-title":"Evidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus.","volume":"9","author":"C Botto","year":"2016","journal-title":"Parasit Vectors."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"178-95","DOI":"10.1016\/j.trstmh.2004.03.012","article-title":"Spatial and temporal variation in biting rates and parasite transmission potentials of onchocerciasis vectors in Ecuador.","volume":"99","author":"J Vieira","year":"2005","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"e2169","DOI":"10.1371\/journal.pntd.0002169","article-title":"Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis.","volume":"7","author":"H Turner","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"56-66","DOI":"10.1016\/j.epidem.2017.02.002","article-title":"Measuring and modelling the effects of systematic non-adherence to mass drug administration.","volume":"18","author":"L Dyson","year":"2017","journal-title":"Epidemics."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"e0003664","DOI":"10.1371\/journal.pntd.0003664","article-title":"Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa.","volume":"9","author":"Y Kim","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13071-015-0779-4","article-title":"The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.","volume":"8","author":"H Turner","year":"2015","journal-title":"Parasit Vectors."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"1199-207","DOI":"10.1093\/cid\/ciu1152","article-title":"Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness.","volume":"60","author":"M Walker","year":"2015","journal-title":"Clin Infect Dis."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13071-018-2864-y","article-title":"Modelling the impact of larviciding on the population dynamics and biting rates of Simulium damnosum (s.l.): implications for vector control as a complementary strategy for onchocerciasis elimination in Africa.","volume":"11","author":"I Routledge","year":"2018","journal-title":"Parasit Vectors."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"e0006702","DOI":"10.1371\/journal.pntd.0006702","article-title":"Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda.","volume":"12","author":"B Jacob","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-53","first-page":"44","article-title":"Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis. Criteria and procedures.","year":"2016"},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"1723-1732","DOI":"10.1093\/aje\/kwz109","article-title":"Predictive Value of Ov16 Antibody Prevalence in Different Subpopulations for Elimination of African Onchocerciasis.","volume":"88","author":"L Coffeng","year":"2019","journal-title":"Am J Epidemiol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"15265-70","DOI":"10.1073\/pnas.0502659102","article-title":"Human infection patterns and heterogeneous exposure in river blindness.","volume":"102","author":"J Filipe","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2458-1-12","article-title":"Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for elimination.","volume":"1","author":"W Alley","year":"2001","journal-title":"BMC Public Health."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13071-018-2655-5","article-title":"Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.","volume":"11","author":"J Cano","year":"2018","journal-title":"Parasit Vectors."},{"key":"ref-58","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz647","article-title":"Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995 to 2025.","author":"N Vinkeles Melchers","year":"2019","journal-title":"Clin Infect Dis."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1338-47","DOI":"10.1093\/cid\/ciw144","article-title":"Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?","volume":"62","author":"K Frempong","year":"2016","journal-title":"Clin Infect Dis."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40249-018-0406-7","article-title":"From river blindness control to elimination: bridge over troubled water.","volume":"7","author":"R Colebunders","year":"2018","journal-title":"Infect Dis Poverty."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"e000158","DOI":"10.1136\/bmjgh-2016-000158","article-title":"Modelling the health and economic impacts of the elimination of river blindness (onchocerciasis) in Africa.","volume":"2","author":"Y Kim","year":"2017","journal-title":"BMJ Glob Health."},{"key":"ref-62","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz461","article-title":"A test-and-not-treat strategy for onchocerciasis elimination in Loa loa co-endemic areas: cost analysis of a pilot in the Soa health district, Cameroon.","author":"E Lenk","year":"2019","journal-title":"Clin Infect Dis."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"e2452","DOI":"10.1371\/journal.pntd.0002452","article-title":"The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study.","volume":"7","author":"H Turner","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"e0005816","DOI":"10.1371\/journal.pntd.0005816","article-title":"Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity.","volume":"11","author":"S Doyle","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13071-015-1283-6","article-title":"Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon.","volume":"8","author":"S Wanji","year":"2015","journal-title":"Parasit Vectors."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"e0005314","DOI":"10.1371\/journal.pntd.0005314","article-title":"Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes.","volume":"11","author":"Y Lont","year":"2017","journal-title":"PLoS Negl Trop Dis."}],"container-title":["Gates Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T21:10:36Z","timestamp":1590095436000},"score":1,"resource":{"primary":{"URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":66,"URL":"https:\/\/doi.org\/10.12688\/gatesopenres.13067.1","relation":{"has-review":[{"id-type":"doi","id":"10.21956\/gatesopenres.14198.r27985","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/gatesopenres.14198.r28085","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/gatesopenres.14198.r27985","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/gatesopenres.14198.r28085","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/gatesopenres.14198.r28086","asserted-by":"object"}]},"ISSN":["2572-4754"],"issn-type":[{"value":"2572-4754","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]},"assertion":[{"value":"Indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/gatesopenres.14198.r27985, James A. Whitworth, London School of Hygiene & Tropical Medicine, London, UK, 22 Oct 2019, version 1, indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1#referee-response-27985","order":0,"name":"referee-response-27985","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/gatesopenres.14198.r28085, Johnny Vlaminck, Department of Virology, Parasitology and Immunology, Ghent University, Merelbeke, Belgium, 22 Oct 2019, version 1, indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/3-1545\/v1#referee-response-28085","order":1,"name":"referee-response-28085","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by the Bill and Mellinda Gates Foundation through funding to the NTD Modelling Consortium [OPP1184344 to MGB, MW, JIDH, CF, SJdV and WAS]. MGB, JIDH and PM acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development [MR\/R015600\/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}